USA - NASDAQ:FBIOP - US34960Q2084
The current stock price of FBIOP is 9 USD. In the past month the price increased by 14.74%. In the past year, price increased by 71.14%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.59 | 385.25B | ||
AMGN | AMGEN INC | 12.41 | 145.72B | ||
GILD | GILEAD SCIENCES INC | 14.37 | 137.97B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 22.71 | 98.65B | ||
REGN | REGENERON PHARMACEUTICALS | 12.15 | 58.78B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
ARGX | ARGENX SE - ADR | 77.26 | 43.83B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.69 | 38.70B | ||
INSM | INSMED INC | N/A | 28.58B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.45B | ||
NTRA | NATERA INC | N/A | 22.24B | ||
BIIB | BIOGEN INC | 8.57 | 20.13B |
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA US
Employees: 101
Phone: 17816524500
The current stock price of FBIOP is 9 USD. The price decreased by -1.21% in the last trading session.
The exchange symbol of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP is FBIOP and it is listed on the Nasdaq exchange.
FBIOP stock is listed on the Nasdaq exchange.
9 analysts have analysed FBIOP and the average price target is 26.69 USD. This implies a price increase of 196.53% is expected in the next year compared to the current price of 9. Check the FORTRESS BIOTECH INC - FBIO 9 3/8 PERP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) has a market capitalization of 267.75M USD. This makes FBIOP a Micro Cap stock.
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) currently has 101 employees.
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) has a support level at 8.95 and a resistance level at 9.47. Check the full technical report for a detailed analysis of FBIOP support and resistance levels.
The Revenue of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) is expected to grow by 43.96% in the next year. Check the estimates tab for more information on the FBIOP EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FBIOP does not pay a dividend.
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) will report earnings on 2025-11-12, after the market close.
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.49).
The outstanding short interest for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) is 0.02% of its float. Check the ownership tab for more information on the FBIOP short interest.
ChartMill assigns a technical rating of 10 / 10 to FBIOP. When comparing the yearly performance of all stocks, FBIOP is one of the better performing stocks in the market, outperforming 90.15% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to FBIOP. FBIOP has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months FBIOP reported a non-GAAP Earnings per Share(EPS) of -2.49. The EPS increased by 37.44% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -15.04% | ||
ROE | -54.76% | ||
Debt/Equity | 1.14 |
9 analysts have analysed FBIOP and the average price target is 26.69 USD. This implies a price increase of 196.53% is expected in the next year compared to the current price of 9.
For the next year, analysts expect an EPS growth of 56.33% and a revenue growth 43.96% for FBIOP